Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline

ADVERTISEMENT RETURN TO ISSUEPREVCorrectionNEXTORIGINAL ARTICLEThis notice is a correctionStriatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of XanomelineCatherine A. ThornCatherine A. ThornInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Catherine A. Thorn, Joshua MoonJoshua MoonInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Joshua Moon, Clinton A. BourbonaisClinton A. BourbonaisInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Clinton A. Bourbonais, John HarmsJohn HarmsInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by John Harms, Jeremy R. EdgertonJeremy R. EdgertonInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Jeremy R. Edgerton, Eda StarkEda StarkInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Eda Stark, Stefanus J. SteynStefanus J. SteynPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Stefanus J. Steyn, Christopher R. ButlerChristopher R. ButlerMedicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United StatesMore by Christopher R. Butlerhttp://orcid.org/0000-0002-9387-5011, John T. LazzaroJohn T. LazzaroPrimary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United StatesMore by John T. Lazzaro, Rebecca E. O'ConnorRebecca E. O'ConnorPrimary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United StatesMore by Rebecca E. O'Connor, and Michael Popiolek*Michael PopiolekInternal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States*E-mail: [email protected]More by Michael Popiolekhttp://orcid.org/0000-0001-7372-1982Cite this: ACS Chem. Neurosci. 2019, 10, 8, 3910Publication Date (Web):July 9, 2019Publication History Published online9 July 2019Published inissue 21 August 2019https://pubs.acs.org/doi/10.1021/acschemneuro.9b00335https://doi.org/10.1021/acschemneuro.9b00335correctionACS PublicationsCopyright © 2019 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views1117Altmetric-Citations8LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (239 KB) Get e-AlertscloseSUBJECTS:Amines,Dairy products,Receptors Get e-Alerts